Molecular diagnostics for determination of HER2 status in breast cancer

Current Diagnostic Pathology

Volumn 9, Issue 1, 2003, Pages 48-55

  Bartlett, J M S ^a   Mallon, E ^b   Cooke, T ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P185; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CHROMOSOME 17; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SCREENING; ONCOGENE NEU; PRACTICE GUIDELINE; PROGNOSIS; QUALITY CONTROL; REVIEW;

EID: 0037308001     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1054/cdip.2002.0155     Document Type: Review

References (56)

1. Konecny G, Pegram M, Untch M et al. HER-2/neu as a predictive marker in breast cancer. Geburtshilfe Frauenheilkunde 2000; 60: 609-619.
2. Ross J S. The HER-2/neu gene and protein in breast cancer: methods of detection and clinical significance. J Clin Ligand Assay 2000; 23: 21-32.
3. Mitchell M S, Press M F. The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999; 26: 108-116.
4. Lohrisch C, Piccart M. An overview of HER2. Semin Oncol 2002; 28: 3-11.
5. Slamon D J, Godolphin W, Jones L A et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
6. Ross J S, Fletcher J A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: 413-418.
7. Andrulis I L, Bull S B, Blackstein M E et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998; 16: 1340-1349.
8. Press M F, Bernstein L, Thomas P A et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-2904.
9. Piffanelli A, Dittadi R, Catozzi L et al. Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters. Breast Cancer Res Treat 1996; 37: 267-276.
10. Press M F. Oncogene amplification and expression. Importance of methodologic considerations. Am J Clin Pathol 1990; 94: 240-241.
11. Press M F, Hung G, Godolphin W, Slamon D J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771-2777.
12. Yarden Y, Sliwkowski M X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
13. Riese D J, Stern D F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998; 20: 41-48.
14. Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
15. Plowman G D, Culouscou J-M, Whitney G S et al. Ligand specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Nat Acad Sci USA 1993; 90: 1746-1750.
16. Lewis S, Locker A, Todd J H et al. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Path 1990; 43: 385-389.
17. Menard S, Tagliabue E, Campiglio M, Pupa S M. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000; 182: 150-162.
18. Cobleigh M A, Vogel C L, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
19. Mehigan B J, Kerin M J. The HER-2/neu story: From oncogene through prognostic marker to therapeutic strategy determinant and monoclonal therapy. Eur J Surg Oncol 1999; 25: 111-112.
20. Schaller G, Bangeman N, Becker C, Buhler H, Opri F, Weitzel H K. Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein. J Cancer Res Clin Oncol 1999; 125: 520-524.
21. Baselga J, Pfister D, Cooper M R et al. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-914.
22. Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063.
23. Olayioye M A, Neve R M, Lane H A, Hynes N E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-3167.
24. Klapper L N, Glathe S, Vaisman N et al. The erbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999; 96: 4995-5000.
25. Guy P M, Platko J V, Cantley L C, Cerione R A, Carraway K L. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 1994; 91: 8132-8136.
26. Pianetti S, Arsura M, Romieu-Mourez R, Coffey R J, Sonenshein G E. Her-2/neu overexpression induces NF-kappaB via a P13-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 2001; 20: 1287-1299.
27. Hynes N E, Horsch K, Olayioye M A, Badache A. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer 2001; 8: 151-159.
28. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic oppotunities. Eur J Cancer 2001; 37: 53-58.
29. Prenzel N, Fischer O M, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001; 8: 11-21.
30. Rodrigues G A, Falasca M, Zhang Z, Ong S H, Schlessinger J. A novel positive feedback loop mediated by the docking protein Gabl and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol Cell Biol 2000; 20: 1448-1459.
31. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286: 1741-1744.
32. Ram T G, Ethier S P. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth Differ 1996; 7: 551-561.
33. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997; 410: 83-86.
34. Alimandi M, Romano A, Curia M C et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995; 10: 1813-1821.
35. Baeckstrom D, Alford D, Taylor-Papadimitriou J. Morphogenetic and proliferative responses to heregulin of mammary epithelial cells in vitro are dependent on HER2 and HER3 and differ from the responses to HER2 homodimerisation or hepatocyte growth factor. Int J Oncol 2000; 16: 1081-1090.
36. Siegel P M, Ryan E D, Cardiff R D, Muller W J. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999; 18: 2149-2164.
37. Chen X, Yeung T K, Wang Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 2000; 277: 757-763.
38. Graus-Porta D, Beerli R R, Daly J M, Hynes N E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-1655.
39. Goldenberg M M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309-318.
40. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismondi P. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994; 14: 1441-1450.
41. Rosen P P, Lesser M L, Arroyo C D, Cranor M, Borgen P, Norton L. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 1995; 75: 1320-1326.
42. Carlomagno C, Perrone F, Gallo C et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14: 2702-2708.
43. Muss H, Berry D, Thor A et al. Lack of interaction of tamoxifen (T) use and ErbB-2/Her-2/Neu (H) expression in CALGB 8541: a randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node positive primary breast cancer (BC). Proc Am Soc Clin Oncol 1999; 18: 68a (Abstract).
44. Paik S, Bryant J, Park C et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-1370.
45. Ravdin P M, Green S, Albain V et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. Proc Am Soc Clin Oncol 1998; 17: 97A (Abstract).
46. Bartlett J M S, Going J J, Mallon E A et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001; 195: 422-428.
47. Reeves J R, Going J J, Smith G, Cooke T G, Ozanne B W, Stanton P D. Quantitative radioimmunohistochemical measurements of p185(erbB-2) in frozen tissue sections. J Histochem Cytochem 1996; 44: 1251-1259.
48. Press M F, Slamon D J, Flom K J, Park J, Zhou J-Y, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 14: 3095-3105.
49. Ellis I O, Dowsett M, Bartlett J et al. Recommendations for HER2 testing in the UK. J Clin Path 2000; 53: 890-892.
50. Fisher C J, Gillett C E, Vojtesek B, Barnes D M, Millis R R. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 1994; 69: 26-31.
51. Going J J, Mallon L, Reeves J R et al. Inter-observer agreement in assessing c-erbB-2 status in breast cancer: immunohistochemistry and FISH. J Pathol 2000; 190: 19A.
52. Helin H J, Helle M J, Kallioniemi O P, Isola J J. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma: correlation with histopathology and DNA flow cytometry. Cancer 1989; 63: 1761-1767.
53. Van Diest P J, van Dam P, Henzen-Logmans S C et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. Clin Pathol 1997; 50: 801-804.
54. Mass R D, Sanders C, Charlene K, et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin Pivotal Trials. ASCO A291 (Abstract). 2000.
55. Pauletti G, Dandekar S, Rong H M, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Onc 2000; 18: 3651-3664.
56. Bartlett J M S, Ellis I O, Mallon E A et al. Analysis of HER2 status in breast cancer: a multicentre comparison of automated image analysis systems versus manual assessment. Breast Cancer Res Treat 2001; 69: 401.